Popular yogurt recalled over possible choking hazard
Danone U.S. recalled all of its YoCrunch products currently available on the market Friday after customers reported plastic pieces in the dome toppers, which hold various sweet treats such as Oreos or M&M's. Sharp-edged plastic pieces could be a choking hazard or pose other risks.
The recall does not apply to the yogurt itself, but only to the yogurt topping container.
Many lot numbers and expiration dates are involved in the recall, spanning from July 7 through September 4. The full list of affected products can be found here.
No injuries or illnesses have currently been reported, and Danone is working alongside the U.S. Food and Drug Administration (FDA).
There are currently no reported illnesses or injuries (YoCrunch)
'The company is working swiftly with retail partners to remove the impacted product from shelves, while it works to address the issue and bring back the YoCrunch products so many people enjoy,' the company said in a press release.
Customers who have purchased any of the recalled products are urged not to consume them and to contact YoCrunch's Customer Care Line using the phone number 1-877-344-4886.
The news of the yogurt's recall comes after Hartford Bakery Inc. recalled its Lewis Bake Shop Artisan Style half-loaf bread after an internal packaging error resulted in visible hazelnuts, an undeclared allergen, in some loaves.
About 883 units from six production lots were mistakenly wrapped and labeled merely as 'May Contain Tree Nuts,' without specifying hazelnuts.
The contamination stems from a packaging changeover from a hazelnut-containing bread batch to the white loaf variant, the company said.
The recalled bread was distributed across 12 states, including Michigan, Wisconsin, Illinois, Indiana, Ohio, Kentucky, Tennessee, Georgia, Arkansas, Missouri, Alabama, and Mississippi.
The bread is packaged in a flexible plastic bag and can be identified by lot codes T10 174010206, T10 174010306, T10 174010406, T10 174020206, T10 174020306, and T10 174020406, which appear on the front panel.
The packaging also includes a net weight of 12 oz, a UPC of 24126018152 on the bottom, and an expiration date of 07/13/2025 displayed on the front panel.
The last two years have seen an alarming and unexplained rise in recalls. In 2024, approximately 300 food recalls were issued, with those recalls being linked to nearly 1,400 illnesses, a Public Interest Research Group report revealed.
Out of the 1,400 illnesses, 487 people became sick enough to require hospitalization, and 19 people died. While those numbers are still low when weighed against the entire U.S. population, they are also double the number of hospitalizations and deaths from foodborne illnesses in 2023.
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 hours ago
- Medscape
Why Are RSV Vaccine Rates so Shockingly Low?
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants and children younger than 2 years. The most severe and life-threatening cases typically affect infants younger than 6 months. However, older toddlers, adults with chronic illnesses or multiple comorbidities, and older adults are also at an elevated risk. Immunization Progress Research on both active and passive RSV immunization has advanced significantly in recent years. Following the approval of the first prophylactic antibody in 2022 and two vaccines in 2023, the prevention of severe RSV illnesses has become increasingly effective. Current strategies include maternal vaccination to protect newborns, immunization of older adults, and passive immunization of infants using the monoclonal antibody nirsevimab. In June, the FDA approved a second monoclonal antibody: clesrovimab. Nirsevimab Nirsevimab (Beyfortus) has been available in the European Union since November 2022. It is indicated for RSV prophylaxis in all infants during their first RSV season and in children up to 2 years of age who are at increased risk during their second season. Nirsevimab is a human monoclonal immunoglobulin G1 (IgG1) kappa antibody produced using recombinant DNA technology. It binds to a highly conserved site on the RSV fusion (F) glycoprotein, which is present only in the prefusion form of the viral surface protein. Nirsevimab has a markedly longer serum half-life than earlier antibodies. The drug is administered as a single intramuscular dose adjusted according to the child's weight. Germany's Standing Committee on Vaccination recommends that infants born between April and September receive antibodies in autumn before their first RSV season. Those born between October and March should receive the vaccine as soon as possible after birth. Clesrovimab Clesrovimab (Enflonsia) is a human monoclonal IgG1 kappa antibody. Unlike nirsevimab, it binds to two sites in both the pre- and post-fusion conformations of the F protein. It is administered as a single intramuscular injection and does not require weight-based dosing. The manufacturer has applied for approval from the European Medicines Agency, and the decision is pending. RSV Vaccines Three RSV vaccines, each targeting a different group, are currently authorized for use in Germany. Arexvy: A monovalent recombinant protein vaccine that includes the RSV F protein and the AS01E adjuvant. It is approved for adults aged 60 years or older. Abrysvo: A bivalent recombinant protein vaccine containing prefusion F antigens from RSV subtypes A and B. It is authorized for use in pregnant women to protect their infants up to 6 months of age and in adults aged 60 years or older. mResvia: Approved in mid-2024, this is the only mRNA RSV vaccine currently available. It is indicated for adults aged 60 years or older and was recently approved in the US for high-risk adults aged 18-59 years. Real-World Data Although clinical trials have demonstrated the strong efficacy of RSV vaccines and antibodies in preventing severe illnesses, data from real-world immunization programs are limited. A new systematic review by UK researchers addressed this gap. Between December 2024 and February 2025, they conducted monthly searches across the Ovid, Embase, MEDLINE, and global health databases. The review included 43 studies that evaluated nirsevimab, maternal RSV vaccination, and adult RSV vaccination. The goal was to assess uptake across countries and demographic groups. Data from more than 1.38 million individuals in Spain, France, Italy, Luxembourg, and the US were analyzed. One study combined records from Catalonia and Andorra. Most data (86%) were drawn from electronic health records and medical registries, and vaccine data were solely from the US. Nirsevimab Uptake In Spain, the uptake of nirsevimab during the 2023-2024 RSV season reached 90.1% (95% CI, 86.4-92.9), the highest of any country reviewed. Infants born during the RSV season and Spanish nationals had higher immunization rates. In the US, 51.2% of eligible infants received nirsevimab in 2023-2024. Uptake was greater among preterm infants, those with at least one comorbidity, and those from Hispanic backgrounds. France recorded 76.5% coverage, with higher rates in infants younger than 3 months than in those aged 3-12 months. Luxembourg reported 83.8%, Italy 68.7%, and Catalonia-Andorra combined 60.2%. Subgroup analyses revealed that children who experienced RSV or other acute respiratory infections were less likely to receive nirsevimab. Maternal Vaccination Maternal RSV vaccine coverage during pregnancy was 30.5% (95% CI, 20.6-42.6). Uptake was significantly lower among women without health insurance or with statutory coverage than among those with private insurance. Black and Hispanic women had lower rates than non-Hispanic White women. Older Adult Vaccination Four population-based studies assessed RSV vaccine uptake in adults aged 60 years or older, showing an average rate of 18.2% (95% CI, 10.8-28.9) in 2023-2024. Uptake was higher among adults older than 75 years, those with comorbidities, and immunocompromised individuals. As with maternal vaccination, the rates were lower among the Black and Hispanic populations. The researchers highlighted the concerningly low uptake among pregnant women and older adults despite the availability of effective prevention tools. They called for coordinated national, clinical, and public health efforts to improve immunization rates in high-risk populations. World Health Organization (WHO) Guidance In May, the WHO published its first position paper on RSV immunization in infants and young children, underscoring global urgency. RSV is the leading cause of pediatric morbidity and mortality. In 2019, an estimated 100,000 children younger than 5 years died from RSV-related lower respiratory tract infections, representing about 2% of all deaths in this age group. Approximately half of these deaths occur in infants younger than 5 months, with 97% occurring in low- and middle-income countries. Globally, RSV accounts for an estimated 3.6 million hospitalizations annually in children younger than 5 years. The WHO recommends that all countries implement immunization programs to prevent severe RSV disease in vulnerable groups. The choice between maternal vaccination and the use of long-acting monoclonal antibodies, such as nirsevimab, should be based on local factors, including health system integration, cost, and overall feasibility. Germany's Robert Koch Institute provides additional guidance in its fact sheets on RSV immunization, including details on nirsevimab and adult vaccinations.
Business Insider
4 hours ago
- Business Insider
NextCure presents new preclinical data on osteogenesis imperfecta treatment
NextCure (NXTC) announced the presentation of new preclinical data in a well-established model of osteogenesis imperfecta demonstrating that treatment with NC605, a novel anti-Siglec-15 antibody, achieved improved bone microarchitecture and reduced fracture incidence compared to anti-sclerostin treatment. The data were presented at the Brittle Bone Society Meeting on July 24th, 2025. These results demonstrate that NC605 could be a highly effective treatment for OI, also known as brittle bone disease. OI is a rare disorder that results in high bone turnover, abnormal bone formation, bone fragility and recurrent fractures. There is no cure for OI. Current anti-resorptive treatments inhibit both bone loss and bone formation leading to an increase in bone density, but overall poor bone quality. In contrast, NC605 has been shown to inhibit bone loss and to produce new bone, with increased quality and density. Fracture incidence and bone architecture were assessed in male and female OI mice treated with weekly 20 mg/kg of surrogate antibody NP159 and compared to control groups treated with twice weekly 50 mg/kg anti-sclerostin or saline. NP159 increased cortical and trabecular bone mineral density, tissue mineral density, cortical thickness and decreased trabecular separation compared to saline-treated mice. 'In a mouse model of moderate-to-severe OI, NP159, a surrogate murine antibody for NC605, improved trabecular and cortical bone density and reduced fracture incidence comparable to anti-sclerostin,' said Priyanka Kothari, Ph.D., NextCure's Director, Translational Research. 'There is currently no standard of care approved by the FDA for patients with OI and NC605 has the potential to provide significant therapeutic benefit for patients.'
UPI
11 hours ago
- UPI
FDA closes investigation into deadly listeria outbreak
The Food and Drug Administration has closed an investigation into a listeria outbreak. It was responsible one death and at least 10 people being sickened. File Photo (2020) Jim Lo Scalzo/EPA July 24 (UPI) -- The Food and Drug Administration has closed an investigation into a listeria outbreak that killed one person and sickened 10 in several western states, health officials announced Thursday. People were sickened by the outbreak after consuming products produced by California-based Fresh & Ready Foods, officials announced Thursday. The recall applied to Ready-to-Eat products sold in Arizona, California, Nevada and Washington. Illnesses have been reported in California and Nevada. Dozens of items have been recalled, ranging from sandwiches and protein snacks to pasta dishes and croissants. "FDA is working with Fresh & Ready Foods on corrective and preventive actions," the FDA said in a statement. The recalled products were distributed between April 18th and April 28th in vending machines and breakrooms in corporate offices, medical buildings and healthcare facilities, the FDA said. The products had "Use By" dates between April 22nd and May19th. The FDA said it made the discovery during environmental testing at a production facility that turned up listeria on a piece of equipment. "Fresh & Ready Foods has taken immediate corrective actions including removing equipment to address this issue to ensure ongoing food safety and compliance with FDA guidelines," the statement continued.
